Abstract #2797

Response Assessment to Tumor Treating Fields in Patients with Glioblastoma using Physiologic and Metabolic MR Imaging

Sanjeev Chawla¹, Sumei Wang¹, Gaurav Verma¹, Aaron Skolnik¹, Sulaiman Sheriff², Katelyn M Reilly¹, Lisa Desiderio¹, Andrew Maudsley², Steven Brem³, Katherine Peters⁴, Harish Poptani⁵, and Suyash Mohan¹

¹Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States, ²Radiology, University of Miami, Miami, FL, United States, ³Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States, ⁴Neurology, Duke University Medical Center, Durham, NC, United States, ⁵Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, United Kingdom

Tumor treating fields (TTFields) are a novel antimitotic treatment modality for treatment of patients with glioblastoma (GBM). To assess response to TTFields, 4 GBM patients underwent diffusion, perfusion and 3D-echo-planar spectroscopic imaging prior to initiation of TTFields and at one and two month follow-up periods. A trend towards increased MD and a decrease in FA and rCBV_max was noted in most patients at 2-month relative to baseline indicating inhibited tumor growth and vascularity. Cho/Cr values did not exhibit any trend probably due to heterogeneity in response. These preliminary data indicate the potential of advanced MR imaging in assessing response to TTFields.

This abstract and the presentation materials are available to members only; a login is required.

Join Here